---
title: "Daiwa Raises BEONE MEDICINES  TP to USD476 as 3Q Again Beats Expectations and Guidance Raised"
type: "News"
locale: "en"
url: "https://longbridge.com/en/news/304959744.md"
description: "Daiwa raised its target price for BeOne Medicines to USD476 and reiterated a Buy rating, citing strong Q3 results and raised full-year guidance. Revenue grew 34% YoY to USD1.89 billion, driven by Brukinsa sales. The broker increased FY2026 revenue guidance to USD6.9-7.0 billion and adjusted EPS forecasts upward, noting that revised targets are easily achievable."
datetime: "2026-11-10T06:00:10.000Z"
locales:
  - [zh-CN](https://longbridge.com/zh-CN/news/304959744.md)
  - [en](https://longbridge.com/en/news/304959744.md)
  - [zh-HK](https://longbridge.com/zh-HK/news/304959744.md)
generator: "portal-rs"
---

# Daiwa Raises BEONE MEDICINES  TP to USD476 as 3Q Again Beats Expectations and Guidance Raised

Daiwa issued a research report stating that BEONE MEDICINES (06160.HK) +4.400 (+1.773%) Short selling $124.15M; Ratio 26.763% again delivered better-than-expected results in the third quarter and raised its full-year guidance. Revenue increased 34% YoY to USD1.89 billion, while product revenue rose 33% YoY to USD1.86 billion, exceeding both the broker's and market expectations, mainly driven by stronger-than-expected sales of Brukinsa. Adjusted non-GAAP net profit increased 77% YoY to USD539 million. Following the second quarter, the company again raised its FY2026 guidance, with revenue guidance lifted from USD6.6 billion-USD6.8 billion to USD6.9 billion-USD7 billion, while non-GAAP operating profit guidance was raised from USD1.7 billion-USD1.8 billion to USD1.9 billion-USD2 billion. The broker believes the revised targets are easily achievable.

The broker noted that global Brukinsa sales remained strong at USD1.4 billion, up 34% YoY and 11% QoQ, driven by continued growth in the US and European Union markets. US sales reached USD1 billion, up 36% YoY and 13% QoQ, including a positive contribution of about USD50 million from order timing. European Union sales rose 33% YoY and 11% QoQ to USD218 million. TEVIMBRA sales also beat expectations, reaching USD243 million, up 28% YoY. Research and development progress was encouraging, with multiple late-stage solid tumor assets advancing toward registration studies. The broker continues to view GPC3×4-1BB as a highly differentiated asset.

The broker reiterated its Buy rating on BeOne Medicines Ltd. (ONC.US) and, based on discounted cash flow valuation, raised its 12-month TP from USD450 to USD476. The broker also raised its 2026-2028 EPS forecasts by 1% to 15%, with its 2027-2028 forecasts standing 7% to 10% above market consensus.(ad/da)(HK stocks quote is delayed for at least 15 mins.Short Selling Data as at 2026-11-10 12:25.) (Real-time Streaming US Stocks Quote; Except All OTC quotes are at least 15 minutes delayed.)

### Related Stocks

- [ONC.US](https://longbridge.com/en/quote/ONC.US.md)
- [06160.HK](https://longbridge.com/en/quote/06160.HK.md)
- [688235.CN](https://longbridge.com/en/quote/688235.CN.md)

## Related News & Research

- [BeOne Medicines: Five solid-tumor programs advance as strong cash flow funds continued pipeline investment](https://longbridge.com/en/news/305810947.md)
- [BeOne commits $3M to expand CLL Society patient education pact](https://longbridge.com/en/news/305853990.md)
- [BeOne Medicines (ONC) Priority Review And Earnings Put Valuation Back In Focus](https://longbridge.com/en/news/304861942.md)
- [Why BeOne Medicines Stock Is In Focus After Earnings Beat And Raised Guidance](https://longbridge.com/en/news/304730912.md)
- [BeOne Medicines presents new data across solid tumor disease areas at ESMO 2026](https://longbridge.com/en/news/303021864.md)

---
> **Disclaimer: This article is for reference only and does not constitute any investment advice.**